Lundbeck announces positive outcome of zicronapine studies

Lundbeck has announced the positive results of two clinical trials into its schizophrenia therapy zicronapine.

A programme was launched by the firm that consisted of two studies involving 375 patients. They both indicated that the drug demonstrated noticeable statistical separation from placebo at 7 and 10 mg doses.

It also demonstrated positive efficacy and safety when compared to existing treatment olanzapine, the firm revealed, prompting it to engage the drug in further development.

Executive vice-president and head of drug development at Lundbeck Anders Gersel Pedersen, commented: “We are […] pleased that the good safety profile seen in earlier studies now is confirmed in a much larger patient population.”

Meanwhile, Lundbeck announced the beginning of a trial into its Alzheimer’s disease (AD) augmentation treatment Lu AE58054 earlier this month.

The multi-centre, placebo-controlled, fixed-dose study will examine the viability of using the treatment as an add-on to donepezil in patients with moderate AD.